{"groups":[{"description":"Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Cycles repeated q21 days to progression/toxicity","id":"FG000","title":"Arm I (Paclitaxel and Cisplatin)"},{"description":"Paclitaxel 135 mg/m2 IV over 24 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 2 Bevacizumab 15 mg/kg IV day 2 OR Paclitaxel 175 mg/m2 IV over 3 hrs on day 1 Cisplatin 50 mg/m2 IV on day 1 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity","id":"FG001","title":"Arm II (Paclitaxel, Cisplatin, Bevacizumab)"},{"description":"Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Cycles repeated q21 days to progression/toxicity","id":"FG002","title":"Arm III (Topotecan Hydrochloride and Paclitaxel)"},{"description":"Paclitaxel 175 mg/m2 over 3 hrs on day 1 Topotecan 0.75 mg/m2 over 30 mins days 1-3 Bevacizumab 15 mg/kg IV day 1 Cycles repeated q21 days to progression/toxicity","id":"FG003","title":"Arm IV (Topotecan Hydrochloride, Paclitaxel, Bevacizumab)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"115"},{"groupId":"FG002","numSubjects":"111"},{"groupId":"FG003","numSubjects":"112"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"115"},{"groupId":"FG002","numSubjects":"111"},{"groupId":"FG003","numSubjects":"112"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The study was activated on 4/6/2009 and closed to accrual on 1/3/2012."}